An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

This study is testing a new formulation of paclitaxel — a standard chemotherapy drug — delivered as a biodegradable wafer implanted directly into the chest after lung surgery, rather than given intravenously. The goal is to provide localized chemotherapy to reduce the risk of the cancer coming back after surgery in patients with early-stage non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 years or older - You have been diagnosed with non-small cell lung cancer (confirmed by biopsy) at stage Ib, IIa, IIb, or IIIa - You have not received any prior chemotherapy or chest radiation - Your surgeon considers you a candidate for complete surgical removal of the cancer - Your blood counts, liver, and kidney functions are within acceptable ranges - You are willing to comply with all study procedures **You may NOT be eligible if...** - You have previously received chest chemotherapy or radiation - Your heart's electrical activity (QT interval) is abnormal - Your organ function does not meet required lab values - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.